---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-228150"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2021-07-29T23:59:59+00:00"
generated_at: "2026-06-30T00:56:15.158711+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Agios Q2 net loss $86.2M, cash $1.7B; CMO retirement, mitapivat NDA submitted

## Summary
- Net loss $86.2M vs $90.5M; cash, cash equivalents and marketable securities $1.7B.
- R&D expenses $62.0M (up from $54.1M) for start-up costs of Phase 3 trials and regulatory filings.
- Completed NDA in U.S. and MAA in EU for mitapivat in adults with PK deficiency.
- Chris Bowden to retire as CMO effective Sept 1; Sarah Gheuens to assume role.
- Repurchased 10.5M shares for $529M at average price $50.41 per share.

## SEC filing metadata
- accession: 0001193125-21-228150
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2021-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312521228150/0001193125-21-228150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312521228150/d108692d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-228150
- JSON: https://secwatch.observer/filing/0001193125-21-228150.json
- Plain text: https://secwatch.observer/filing/0001193125-21-228150.txt

## Key facts
- Executive change
  Christopher Bowden resigned as chief medical officer at AGIOS PHARMACEUTICALS, INC..
  - Action: resigned
  - Role: chief medical officer
  source text: On July 27, 2021, Christopher Bowden notified the Company of his intention to resign as chief medical officer of the Company, effective September 1, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000119312521228150/0001193125-21-228150-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.